tiprankstipranks
Trending News
More News >
Marpai (MRAI)
OTHER OTC:MRAI
US Market
Advertisement

Marpai (MRAI) AI Stock Analysis

Compare
104 Followers

Top Page

MRAI

Marpai

(OTC:MRAI)

Rating:44Neutral
Price Target:
$1.50
▲(7.14% Upside)
Marpai's overall stock score is heavily influenced by its challenging financial performance marked by declining revenues and negative equity. While technical analysis and corporate events provide some positive signals, the financial difficulties remain the most critical concern. Improvements in operating efficiencies and strategic initiatives are encouraging but require more time to impact the company's stability.

Marpai (MRAI) vs. SPDR S&P 500 ETF (SPY)

Marpai Business Overview & Revenue Model

Company DescriptionMarpai, Inc., a technology-driven healthcare payer, focuses on providing services to the self-insured employer market in the United States and Israel. The company offers ancillary services, such as care management, case management, actuarial services, health savings account administration, and cost containment services. It also develops artificial intelligence and healthcare technology that enables the analysis of data to predict and prevent events related to diagnostic errors, hospital visits, and administrative issues. The company was incorporated in 2021 and is headquartered in New York, New York.
How the Company Makes MoneyMarpai generates revenue primarily through its health plan administration services offered to self-insured employers. The company charges fees for managing health plans, which include claims processing, network management, and customer support. Marpai's use of AI and machine learning enhances its service offerings, enabling clients to benefit from predictive analytics and tailored health interventions aimed at reducing healthcare costs and improving employee health outcomes. Significant partnerships with healthcare providers and technology firms also contribute to its service capabilities, potentially increasing its client base and revenue.

Marpai Earnings Call Summary

Earnings Call Date:Aug 13, 2025
(Q1-2025)
|
% Change Since: -2.78%|
Next Earnings Date:Nov 17, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant improvements in operating efficiencies and a strong outlook for future growth, despite a notable decline in revenue and substantial cash burn in the first quarter.
Q1-2025 Updates
Positive Updates
Improved Operating and Net Losses
Operating loss was $2.3 million for Q1 2025, showing a 45% improvement over Q1 2024. Net loss was $3.1 million, a 29% improvement over the previous year.
Operating Expenses Reduction
Operating expenses were reduced by 33% to $7.7 million for the first quarter of 2025 compared to Q1 2024.
Positive Outlook for Future Growth
Strong pipeline for the second half of 2025, with anticipated cash flow positivity by year-end and potential growth in 2026.
Leadership Strengthening
Appointment of Dallas Scrip as Chief Operating Officer and President of MarpaiRx to enhance growth initiatives.
Launch of Empower Member Portal
Empower member portal rollout is on track, aiming to improve customer experience and operational efficiencies.
Negative Updates
Revenue Decline
Net revenues were $5.4 million, approximately 27% lower than Q1 2024.
Significant Cash Burn
Burned $3 million in the first quarter, raising concerns about reaching cash flow positive status.
Slower New Business Acquisition
Lower than expected new business sign-ups in Q1 2025, attributed to late hiring of key sales personnel.
Company Guidance
During the Marpai First Quarter 2025 Earnings Webcast, CFO Steve Johnson reported that the company's net revenues were $5.4 million for the quarter ending March 31, 2025, a decrease of approximately 27% compared to the previous year. However, there were improvements in operating expenses, which were $7.7 million, representing a 33% improvement over Q1 2024, and operating loss, which improved by 45% to $2.3 million. The net loss for the quarter was $3.1 million, a 29% enhancement from the prior year. Earnings per share were reported as a loss of $0.21, which was a $0.25 per share improvement from the first quarter of 2024. The company remains focused on enhancing profitability and reducing costs, with a goal to achieve cash flow positivity by the end of the year. Additionally, Marpai is leveraging its role as a third-party administrator (TPA) to capitalize on the growing TPA market, which is projected to grow annually by 12.1% through 2031.

Marpai Financial Statement Overview

Summary
Marpai faces substantial financial difficulties, including continuous net losses, declining revenues, negative equity, and significant cash burn. Despite minor improvements, the overall financial position remains precarious.
Income Statement
45
Neutral
Marpai's income statement reveals a challenging financial position with continuous net losses and a declining revenue trend. The gross profit margin shows some improvement, but the company struggles with negative EBIT and net profit margins. Revenue decreased by 24% from the previous year, indicating potential issues with sales growth and market conditions.
Balance Sheet
30
Negative
The balance sheet of Marpai shows significant financial stress, with negative stockholders' equity and high liabilities compared to assets. The debt-to-equity ratio is not applicable due to negative equity, and the company's equity ratio is negative, suggesting insolvency. These factors indicate a precarious financial position and reliance on external funding.
Cash Flow
40
Negative
Marpai's cash flow statement highlights negative free cash flow and operating cash flow, indicating cash burn issues. Although there is some improvement in financing cash flow, it is insufficient to cover operating cash needs. The free cash flow to net income ratio remains negative, pointing to ongoing cash management challenges.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue28.17M37.16M24.34M14.23M0.00
Gross Profit9.11M12.92M7.21M3.94M-152.37K
EBITDA-23.73M-22.12M-22.55M-13.80M-3.19M
Net Income-22.09M-28.75M-26.47M-15.98M-4.41M
Balance Sheet
Total Assets12.88M31.68M49.95M44.20M6.53M
Cash, Cash Equivalents and Short-Term Investments764.00K1.15M13.76M19.18M1.75M
Total Debt1.04M4.20M6.08M2.09M9.34M
Total Liabilities40.59M45.12M43.82M14.49M10.03M
Stockholders Equity-27.71M-13.44M6.13M29.71M-3.50M
Cash Flow
Free Cash Flow-15.16M-15.75M-36.20M-12.54M-2.55M
Operating Cash Flow-15.16M-15.75M-35.24M-10.79M-1.95M
Investing Cash Flow227.00K1.03M32.42M9.64M-554.07K
Financing Cash Flow10.67M5.10M196.0025.27M4.08M

Marpai Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.40
Price Trends
50DMA
1.34
Positive
100DMA
1.23
Positive
200DMA
1.13
Positive
Market Momentum
MACD
0.02
Negative
RSI
53.90
Neutral
STOCH
87.33
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MRAI, the sentiment is Positive. The current price of 1.4 is above the 20-day moving average (MA) of 1.34, above the 50-day MA of 1.34, and above the 200-day MA of 1.13, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 53.90 is Neutral, neither overbought nor oversold. The STOCH value of 87.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MRAI.

Marpai Risk Analysis

Marpai disclosed 23 risk factors in its most recent earnings report. Marpai reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Marpai Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
$3.82B49.61-14.04%48.29%-1436.25%
65
Neutral
$8.53B7.9523.93%16.12%10.99%
58
Neutral
$12.85B6.697.50%12.96%-23.25%
55
Neutral
$2.93B-38.50%49.46%66.89%
51
Neutral
$7.44B-0.20-46.00%2.27%22.80%-2.27%
50
Neutral
$1.32B-12.59%-4.87%66.16%
44
Neutral
$24.18M94.19%-24.84%43.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
MRAI
Marpai
1.40
0.85
154.55%
CNC
Centene
26.93
-51.18
-65.52%
MOH
Molina Healthcare
159.63
-190.34
-54.39%
CLOV
Clover Health Investments
2.57
-0.26
-9.19%
OSCR
Oscar Health
14.68
-4.02
-21.50%
ALHC
Alignment Healthcare
14.82
6.12
70.34%

Marpai Corporate Events

Private Placements and Financing
Marpai Announces New Securities Purchase Agreement
Positive
Aug 4, 2025

Marpai, Inc. announced on August 4, 2025, that it has entered into a Securities Purchase Agreement with investor parties, dated July 29, 2025. This agreement marks a significant step for Marpai, potentially impacting its financial operations and market positioning.

Private Placements and FinancingRegulatory Filings and Compliance
Marpai Enters Securities Purchase Agreement July 2025
Neutral
Jul 21, 2025

On July 17, 2025, Marpai Health Inc. entered into a Securities Purchase Agreement with investor parties, as documented in a recent filing. This agreement marks a significant step in Marpai’s financial strategy, potentially impacting its market position and stakeholder interests.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 05, 2025